Imagion Biosystems has released Appendix 3Z Final Director’s Interest Notice. Read the Final Director’s Interest Notice.
Final Director's Interest Notice
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.